Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00955435 |
Recruitment Status :
Active, not recruiting
First Posted : August 10, 2009
Last Update Posted : February 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This clinical trial is studying blood and urine samples in patients with newly diagnosed localized prostate cancer treated with hormone therapy and radiation therapy.
Condition or disease | Intervention/treatment |
---|---|
Prostate Cancer | Other: Non-interventional Genetic: Protein expression analysis Genetic: Proteomic profiling Other: Laboratory biomarker analysis |
OBJECTIVES:
- Detect changes in serum and urine proteomic profiles that predict outcome in patients with newly diagnosed localized prostate cancer treated with hormonal therapy and radiotherapy.
- Identify prognostic and biochemical markers of early disease progression in patients treated with this regimen.
- Identify unique protein expression and temporal alterations, in these profiles, that facilitate understanding of the factors predicting relapse or toxicity.
- Identify molecular signatures that allow identification of targets for therapeutic intervention.
OUTLINE: This is a multicenter study.
Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy (per standard treatment). Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.NOTE: * Patients receiving short-term hormonal treatment for 4-8 months are eligible to participate in the trial.
Blood and urine samples are collected at baseline, and periodically during and after induction therapy for proteomic analysis.
After completion of study therapy, patients are followed up periodically for 5 years and yearly thereafter for the duration of the trial.
Study Type : | Observational |
Actual Enrollment : | 60 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer |
Actual Study Start Date : | February 2006 |

- Other: Non-interventional
Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
- Genetic: Protein expression analysis
- Genetic: Proteomic profiling
- Other: Laboratory biomarker analysis
- Changes in serum and urine proteomic profiles [ Time Frame: Ongoing until patient progression ]
- Prognostic and biochemical markers of early disease progression [ Time Frame: Ongoing until patient progression ]
- Protein expression and temporal alterations [ Time Frame: Ongoing until patient progression ]
- Molecular targets [ Time Frame: Ongoing until patient progression ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion criteria:
- Age 18 years or over.
- Histologically confirmed invasive adenocarcinoma of the prostate (by TURP or TRUS).
- Localised prostate cancer with a Gleason score 7
- Short term hormonal treatment 4-8 months
- Performance status of KPS ≥ 60 / WHO 0-2
- Absence of distant metastases
Exclusion criteria:
- The patient has previously received treatment for prostate cancer other than TURP/ TRUS
- The patient has had a bilateral orchidectomy
- The patient has previously received hormonal treatment for prostate cancer
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. In the opinion of the investigator, any evidence of severe or uncontrolled systematic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease
- The patient has or had other co-existing malignancies within the past 5 years other than non- melanoma skin cancer
- Treatment with non-approved or investigational drug within 30 days before day one of the trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00955435
Ireland | |
Beacon Hospital | |
Dublin, Ireland, 18 | |
Saint Luke's Radiation Oncology Network | |
Dublin, Ireland, 6 |
Principal Investigator: | John Gerard Armstrong, MD, MB, MRCPI | Saint Luke's Hospital |
Responsible Party: | Cancer Trials Ireland |
ClinicalTrials.gov Identifier: | NCT00955435 |
Other Study ID Numbers: |
CTRIAL-IE (ICORG) 06-15 CTRIAL-IE (ICORG) 06-15 EU-20921 |
First Posted: | August 10, 2009 Key Record Dates |
Last Update Posted: | February 18, 2021 |
Last Verified: | February 2021 |
adenocarcinoma of the prostate stage I prostate cancer stage IIB prostate cancer stage IIA prostate cancer stage III prostate cancer |
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Neoplasms Prostatic Diseases |